Compare BHVN & BST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BHVN | BST |
|---|---|---|
| Founded | 2013 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.7B |
| IPO Year | 2022 | 2014 |
| Metric | BHVN | BST |
|---|---|---|
| Price | $14.38 | $45.39 |
| Analyst Decision | Buy | |
| Analyst Count | 14 | 0 |
| Target Price | ★ $29.08 | N/A |
| AVG Volume (30 Days) | ★ 2.9M | 80.6K |
| Earning Date | 05-11-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 10.06% |
| EPS Growth | ★ 26.08 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.48 | $34.87 |
| 52 Week High | $18.57 | $51.30 |
| Indicator | BHVN | BST |
|---|---|---|
| Relative Strength Index (RSI) | 49.18 | 42.03 |
| Support Level | $14.17 | $44.32 |
| Resistance Level | $17.01 | $46.35 |
| Average True Range (ATR) | 0.99 | 0.92 |
| MACD | -0.29 | -0.30 |
| Stochastic Oscillator | 20.49 | 16.03 |
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder and others. Its pipeline products include: BHV-2000, BHV-7000, BHV-2100, BHV-8000, BHV-1310, BHV-1300, BHV-1400, BHV-1600, BHV-1530, and BHV-1500.
BlackRock Science and Technology Trust is a closed-end management investment company. Its investment objectives are to provide total return and income through long-term capital appreciation.